SK Biopharmaceuticals Co., Ltd.
326030
Rang in aandelen
#4039
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Aandeelprijs
$51.31
Marktkapitalisatie
$4.02B
Verandering (1 dag)
-2.62%
Verandering (1 jaar)
-28.88%
Land
KR
Handel SK Biopharmaceuticals Co., Ltd. (326030)
Categorie
Healthcare
EPS voor SK Biopharmaceuticals Co., Ltd. (326030)
EPS per June 2026 TTM: $3.42
Volgens de laatste financiële rapporten en de aandelenkoers van SK Biopharmaceuticals Co., Ltd. is de huidige EPS van het bedrijf (TTM) $3.42. Eind 2024 had het bedrijf een EPS van $2.09, een stijging ten opzichte van de EPS van 2023 die $-0.32 bedroeg.
EPS-geschiedenis van SK Biopharmaceuticals Co., Ltd. van 2011 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $3.42 | 52.67% |
| 2025 | $2.24 | 7.31% |
| 2024 | $2.09 | -743.06% |
| 2023 | $-0.32 | -77.01% |
| 2022 | $-1.41 | -302.57% |
| 2021 | $0.70 | -121.93% |
| 2020 | $-3.18 | 233.25% |
| 2019 | $-0.95 | -52.18% |
| 2018 | $-1.99 | 8.75% |
| 2017 | $-1.83 | 264.02% |
| 2016 | $-0.50 | 5.40% |
| 2015 | $-0.48 | -30.23% |
| 2014 | $-0.68 | -29.69% |
| 2013 | $-0.97 | 36.72% |
| 2012 | $-0.71 | 69.47% |
| 2011 | $-0.42 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $17.32 | 406.48% |
US
|
|
| $-7.98 | -333.35% |
US
|
|
| $-5.29 | -254.69% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 711.18% |
NL
|
